Moderna Inc
As on 23 May, 2025 | 01:29 IST
| Open | 25.75 |
| Previous Close | 25.81 |
| Beta | -0.01 |
| High | 28.07 |
| Low | 25.22 |
| TTM EPS See historical trend | -8.73(+44.29% YoY) |
| 52 Week High | 169.92 |
| 52 Week Low | 23.24 |
| TTM PE See historical trend | -3.06(Low PE) |
| Mkt. Cap ($ Billion) | 10.23 |
| Dividend Yield | -- |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 26.35 |
| 10 | 25.49 |
| 20 | 26.06 |
| 50 | 28.09 |
| 100 | 32.43 |
| 200 | 47.59 |
Returns
| 1 Week | 13.00% | |
| 1 Month | 3.76% | |
| 3 Months | -24.76% | |
| YTD | -35.67% | |
| 1 Year | -83.61% | |
| 3 Years | -80.38% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Amgen | 313.69 | 0.42 | 163.24 | 17.49 | 17.42 | 3.52 | 329.72/215.32 | -1.81 | Bearish |
| Gilead Sciences | 112.54 | -1.21 | 140.23 | 16.10 | 6.99 | 3.89 | 115.22/0.00 | 8.07 | Bearish |
| Vertex Pharmaceuticals | 392.16 | 0.79 | 101.21 | 26.53 | 14.78 | -- | 392.45/0.00 | -14.65 | Bearish |
| Regeneron Pharmaceuticals | 579.56 | -1.26 | 62.92 | 13.03 | 44.48 | -- | 597.02/0.00 | -14.03 | Bullish |
| Biogen | 139.38 | -0.40 | 32.86 | 13.13 | 17.21 | -- | 319.76/189.55 | 1.98 | Very Bearish |
Market news
- S&P 500 ends lower as Dell and Nvidia dropAugust 30, 2025 10:46 AM
- Dow notches record high as Wall Street cheers Powell's speechAugust 23, 2025 10:31 AM
- Dow ends higher after UnitedHealth gains, other indexes slip on rate cut uncertaintyAugust 16, 2025 11:08 AM
- Stocks slump on latest tariffs, soft jobs dataAugust 2, 2025 11:55 AM
About the company
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.